Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 19 | 2019 | 489 | 2.540 |
Why?
|
| Airway Remodeling | 11 | 2017 | 22 | 2.210 |
Why?
|
| Tomography, X-Ray Computed | 23 | 2023 | 1663 | 1.620 |
Why?
|
| Lung | 8 | 2020 | 969 | 0.750 |
Why?
|
| Filariasis | 1 | 2022 | 23 | 0.720 |
Why?
|
| Forced Expiratory Volume | 8 | 2019 | 213 | 0.700 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 326 | 0.680 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2023 | 21 | 0.670 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2023 | 22 | 0.670 |
Why?
|
| Calcium | 2 | 2022 | 587 | 0.610 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 137 | 0.590 |
Why?
|
| Myocardium | 1 | 2021 | 302 | 0.580 |
Why?
|
| Vital Capacity | 4 | 2019 | 123 | 0.570 |
Why?
|
| Fistula | 1 | 2018 | 17 | 0.560 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2018 | 20 | 0.550 |
Why?
|
| Mitral Valve | 2 | 2021 | 126 | 0.550 |
Why?
|
| Calcinosis | 1 | 2018 | 84 | 0.530 |
Why?
|
| Lacrimal Apparatus | 2 | 2020 | 5 | 0.520 |
Why?
|
| Predictive Value of Tests | 10 | 2023 | 1117 | 0.510 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 712 | 0.510 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 98 | 0.500 |
Why?
|
| Bronchiectasis | 3 | 2019 | 15 | 0.470 |
Why?
|
| Severity of Illness Index | 9 | 2019 | 1569 | 0.450 |
Why?
|
| Neoplasms | 2 | 2022 | 1378 | 0.430 |
Why?
|
| Penile Neoplasms | 1 | 2014 | 1 | 0.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2017 | 708 | 0.420 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 233 | 0.410 |
Why?
|
| Penis | 1 | 2014 | 37 | 0.410 |
Why?
|
| Algorithms | 2 | 2020 | 1060 | 0.390 |
Why?
|
| Lymph Nodes | 1 | 2014 | 237 | 0.380 |
Why?
|
| Humans | 43 | 2024 | 65845 | 0.380 |
Why?
|
| Image Enhancement | 1 | 2014 | 196 | 0.370 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 190 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 2324 | 0.370 |
Why?
|
| Orbital Neoplasms | 1 | 2011 | 7 | 0.350 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2011 | 9 | 0.350 |
Why?
|
| Pulmonary Emphysema | 4 | 2016 | 109 | 0.330 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2024 | 109 | 0.320 |
Why?
|
| Eosinophilia | 4 | 2013 | 37 | 0.320 |
Why?
|
| Phenotype | 8 | 2016 | 1236 | 0.320 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 327 | 0.280 |
Why?
|
| Interleukin-5 | 3 | 2014 | 37 | 0.280 |
Why?
|
| Bronchi | 3 | 2017 | 86 | 0.270 |
Why?
|
| Sputum | 5 | 2019 | 44 | 0.270 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2022 | 68 | 0.260 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 171 | 0.260 |
Why?
|
| Male | 25 | 2023 | 31410 | 0.260 |
Why?
|
| Female | 24 | 2023 | 34425 | 0.260 |
Why?
|
| Adult | 15 | 2022 | 17579 | 0.240 |
Why?
|
| Middle Aged | 20 | 2023 | 18501 | 0.210 |
Why?
|
| Aged | 15 | 2023 | 15147 | 0.200 |
Why?
|
| Cluster Analysis | 2 | 2015 | 267 | 0.200 |
Why?
|
| Fibroblasts | 2 | 2016 | 423 | 0.200 |
Why?
|
| Microfilariae | 1 | 2022 | 4 | 0.180 |
Why?
|
| Computed Tomography Angiography | 2 | 2024 | 143 | 0.180 |
Why?
|
| Ovary | 1 | 2022 | 105 | 0.170 |
Why?
|
| Contrast Media | 2 | 2021 | 435 | 0.170 |
Why?
|
| Vascular Calcification | 1 | 2021 | 27 | 0.170 |
Why?
|
| Terminal Care | 1 | 2022 | 123 | 0.170 |
Why?
|
| Coronary Angiography | 1 | 2022 | 212 | 0.170 |
Why?
|
| Cardiology | 1 | 2023 | 172 | 0.170 |
Why?
|
| Orbital Pseudotumor | 1 | 2020 | 1 | 0.170 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2020 | 15 | 0.160 |
Why?
|
| Nephritis, Interstitial | 1 | 2020 | 16 | 0.160 |
Why?
|
| Fibrosis | 1 | 2021 | 172 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 102 | 0.150 |
Why?
|
| Biomarkers | 6 | 2016 | 1503 | 0.150 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 107 | 0.150 |
Why?
|
| Endovascular Procedures | 2 | 2024 | 633 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 63 | 0.150 |
Why?
|
| Consumer Behavior | 1 | 2019 | 38 | 0.150 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2021 | 118 | 0.150 |
Why?
|
| Orthopedics | 1 | 2019 | 35 | 0.150 |
Why?
|
| Aneurysm, Infected | 1 | 2019 | 13 | 0.150 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 14 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 121 | 0.140 |
Why?
|
| Aortography | 1 | 2019 | 58 | 0.140 |
Why?
|
| Curriculum | 1 | 2023 | 609 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1172 | 0.140 |
Why?
|
| Aneurysm, False | 1 | 2019 | 47 | 0.140 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2018 | 25 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 162 | 0.140 |
Why?
|
| Kidney | 1 | 2020 | 460 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 202 | 0.130 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2018 | 117 | 0.130 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2016 | 9 | 0.130 |
Why?
|
| Pediatrics | 1 | 2019 | 265 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2019 | 398 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 417 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6957 | 0.120 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 117 | 0.110 |
Why?
|
| Pregnancy | 1 | 2022 | 2401 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 634 | 0.100 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 61 | 0.100 |
Why?
|
| Bronchography | 2 | 2011 | 5 | 0.100 |
Why?
|
| Bacteria | 1 | 2017 | 337 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 94 | 0.100 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2014 | 12 | 0.100 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2014 | 66 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 256 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2015 | 606 | 0.100 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 51 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 554 | 0.090 |
Why?
|
| Bronchial Diseases | 1 | 2012 | 13 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 1719 | 0.090 |
Why?
|
| Actinomycosis | 1 | 2012 | 5 | 0.090 |
Why?
|
| ROC Curve | 2 | 2011 | 295 | 0.090 |
Why?
|
| After-Hours Care | 1 | 2012 | 9 | 0.090 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2012 | 8 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 180 | 0.090 |
Why?
|
| Animals | 3 | 2022 | 21493 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2012 | 32 | 0.090 |
Why?
|
| Angiography | 1 | 2012 | 154 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2019 | 2090 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 106 | 0.080 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2010 | 1 | 0.080 |
Why?
|
| Eosinophil Peroxidase | 1 | 2010 | 1 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 67 | 0.080 |
Why?
|
| Neutrophil Infiltration | 1 | 2010 | 64 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2012 | 198 | 0.070 |
Why?
|
| Bronchitis | 1 | 2009 | 30 | 0.070 |
Why?
|
| Observer Variation | 1 | 2009 | 217 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 2739 | 0.070 |
Why?
|
| Time Factors | 1 | 2015 | 3779 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2012 | 731 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2024 | 5834 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 715 | 0.060 |
Why?
|
| Logistic Models | 1 | 2009 | 1274 | 0.060 |
Why?
|
| Obesity | 1 | 2013 | 1281 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 1042 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 875 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 800 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 993 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2024 | 80 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2016 | 664 | 0.050 |
Why?
|
| Respiratory Function Tests | 2 | 2016 | 195 | 0.050 |
Why?
|
| Adolescent | 3 | 2022 | 6368 | 0.050 |
Why?
|
| Aorta | 1 | 2024 | 108 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2790 | 0.050 |
Why?
|
| Ontario | 1 | 2022 | 58 | 0.050 |
Why?
|
| United States | 3 | 2023 | 8189 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 104 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1148 | 0.040 |
Why?
|
| Eosinophils | 2 | 2013 | 51 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2013 | 102 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5682 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2021 | 125 | 0.040 |
Why?
|
| Stents | 1 | 2024 | 500 | 0.040 |
Why?
|
| Palliative Care | 1 | 2022 | 251 | 0.040 |
Why?
|
| Meaningful Use | 1 | 2019 | 9 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 809 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 199 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 77 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2019 | 29 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 48 | 0.040 |
Why?
|
| Gadolinium | 1 | 2019 | 111 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2021 | 293 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 146 | 0.040 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2020 | 110 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 74 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2019 | 346 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 284 | 0.030 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 190 | 0.030 |
Why?
|
| Prevotella | 1 | 2017 | 2 | 0.030 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2017 | 11 | 0.030 |
Why?
|
| Streptococcus | 1 | 2017 | 19 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2017 | 31 | 0.030 |
Why?
|
| United Kingdom | 1 | 2017 | 86 | 0.030 |
Why?
|
| Young Adult | 2 | 2022 | 4883 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 107 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 128 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 194 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 276 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 405 | 0.030 |
Why?
|
| Respiratory System | 1 | 2016 | 46 | 0.030 |
Why?
|
| Software | 1 | 2019 | 401 | 0.030 |
Why?
|
| Spirometry | 1 | 2016 | 114 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 262 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 200 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2019 | 277 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 370 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2014 | 3340 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1454 | 0.030 |
Why?
|
| Inflammation | 2 | 2012 | 1198 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 932 | 0.030 |
Why?
|
| Microbiota | 1 | 2017 | 171 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2116 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 233 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 491 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 449 | 0.020 |
Why?
|
| Chemokine CCL11 | 1 | 2013 | 4 | 0.020 |
Why?
|
| England | 1 | 2013 | 28 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 54 | 0.020 |
Why?
|
| Interleukin-1alpha | 1 | 2013 | 25 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2013 | 33 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 65 | 0.020 |
Why?
|
| Quality of Life | 2 | 2011 | 1266 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 484 | 0.020 |
Why?
|
| Actinomyces | 1 | 2012 | 1 | 0.020 |
Why?
|
| Forearm | 1 | 2012 | 23 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 129 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2012 | 88 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 60 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 105 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5475 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 274 | 0.020 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2011 | 18 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 65 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1391 | 0.020 |
Why?
|
| Mast Cells | 1 | 2011 | 51 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 676 | 0.020 |
Why?
|
| Neutrophils | 1 | 2013 | 396 | 0.020 |
Why?
|
| Child | 1 | 2019 | 4653 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 901 | 0.020 |
Why?
|
| Prednisolone | 1 | 2009 | 11 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2009 | 26 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 183 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 856 | 0.020 |
Why?
|
| Health Status | 1 | 2011 | 448 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2500 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2009 | 165 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 737 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 462 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 747 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1193 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 1100 | 0.010 |
Why?
|
| Hospitalization | 1 | 2009 | 1404 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3170 | 0.010 |
Why?
|